Currently, there are no clinical guidelines for clinicians around PSA level thresholds to trigger further prostate investigations in TWNBPP receiving GAHT, who are at risk of, or who are being investigated for the presence of, prostate cancer. This evidence concerns the gene KLK3 and prostate cancer.